Check Cap (CHEK) Given a $14.00 Price Target by HC Wainwright Analysts
Check Cap (NASDAQ:CHEK) has been assigned a $14.00 target price by stock analysts at HC Wainwright in a report released on Friday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 378.63% from the stock’s current price.
Shares of CHEK opened at $2.93 on Friday. Check Cap has a 12-month low of $3.08 and a 12-month high of $19.78.
Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Monday, November 5th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.03. As a group, research analysts forecast that Check Cap will post -2.57 EPS for the current fiscal year.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.